Abstract
Type 1 diabetes is a chronic autoimmune condition that requires life-long insulin administration. An increasing prevalence of diabetes, especially in youngest children, results in significant burden on the healthcare system.
Unsatisfactory disease control is associated with the development of long-term micro- and macrovascular complications, which significantly affect the quality of life and life expectancy of our patients. The current treatment goal in paediatric patients is to achieve normoglycemia and to completely eliminate the occurrence of secondary complications of diabetes.
Modern technologies have been successfully implemented as the standard of care for people with Type 1 diabetes and have improved the glycaemic control by reducing time spent both in hyper- and hypoglycaemia, while improving quality of life of our patients. Their overview and their pathway to our patients are presented in this review.